Clinical Trials Logo

Pulmonary Arterial Hypertension clinical trials

View clinical trials related to Pulmonary Arterial Hypertension.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT01897740 No longer available - Clinical trials for Pulmonary Arterial Hypertension

Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide Sildenafil therapy for subjects who completed A1481156 study and are judged by the investigator to derive clinical benefit from continued treatment with Sildenafil, prior to reimbursement and availability for subjects in the Russian Federation.

NCT ID: NCT01582438 No longer available - Clinical trials for Pulmonary Arterial Hypertension

An Open Label Access Study For Subjects Who Completed A1481156

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide sildenafil therapy to subjects who have completed the A1481156 study for the treatment of Pulmonary Arterial Hypertension (PAH) in India and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil citrate. Sildenafil citrate will be supplied for the treatment of Pulmonary Arterial Hypertension (PAH) until the subject continues to derive benefits from the treatment. The treating physicians (and the sponsor) will be responsible for reporting serious adverse events.

NCT ID: NCT00878943 No longer available - Clinical trials for Pulmonary Arterial Hypertension

Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study

UK 92480
Start date: n/a
Phase:
Study type: Expanded Access

In an earlier study, sildenafil citrate administered to patients of PAH led to improvement in pulmonary arterial pressure, cardiac output, quality of life, and other parameters as compared to placebo. This protocol provides mechanism for patients who have clinical deterioration on other PAH approved therapies to have access to sildenafil prior to marketing authorization in India.

NCT ID: NCT00866983 No longer available - Clinical trials for Pulmonary Arterial Hypertension

Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide sildenafil therapy to patients who completed the A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio™ is not supplied by Health Secretary, and are judged by the Investigator to derive clinical benefit from continued treatment with Sildenafil. It will be supplied until patient gets access to Sildenafil through Brazilian State Health Secretary from where patient resides.